Sanjiv Sharma
Experienced in Vasculitis

Dr. Sanjiv Sharma

Cardiology | Interventional Cardiology
CommonSpirit Health
Centric Health
2901 Sillect Ave, Ste 100, 
Bakersfield, CA 
Accepting New Patients
Offers Telehealth

Experienced in Vasculitis
CommonSpirit Health
Centric Health
2901 Sillect Ave, Ste 100, 
Bakersfield, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Our doctors are dedicated to treating you as an individual and advancing the research needed to provide a better way of life for you and your loved ones.

Dr. Sharma is rated as an Experienced provider by MediFind in the treatment of Vasculitis. His top areas of expertise are Angina, Coronary Heart Disease, Atherosclerosis, Coronary Artery Spasm, and Angioplasty.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
All India Institute Of Medical Sciences
Residency
Boston Univ School of Medicine
Specialties
Cardiology
Interventional Cardiology
Licenses
Internal Medicine in CA
Board Certifications
Internal Medicine (Sub: Cardiovascular Disease)
Internal Medicine (Sub: Interventional Cardiology)
Fellowships
Cedars-Sinai Medical Center
VA Medical Center (W LA)
Hospital Affiliations
Dignity Health – Memorial Hospital
Languages Spoken
English
Hindi
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Centric Health
2901 Sillect Ave, Ste 100, Bakersfield, CA 93308
Call: 661-323-8384

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


26 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 07, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
Enrollment Status: Completed
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drug: BPN14770
Study Phase: Phase 2
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
Enrollment Status: Withdrawn
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease
A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Unknown
Publish Date: March 25, 2020
Intervention Type: Drug
Study Drug: AD-35
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Enrollment Status: Completed
Publish Date: October 24, 2018
Intervention Type: Drug
View 25 Less Clinical Trials

5 Total Publications

Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Journal: Advances in therapy
Published: November 22, 2018
View All 5 Publications
Similar Doctors
Sarabjeet Singh
Distinguished in Vasculitis
Dr. Sarabjeet Singh
Cardiology | Interventional Cardiology
Distinguished in Vasculitis
Dr. Sarabjeet Singh
Cardiology | Interventional Cardiology

Centric Health

2901 Sillect Ave, Ste 100, 
Bakersfield, CA 
 (0.1 miles away)
661-323-8384
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarabjeet Singh is a Cardiologist and an Interventional Cardiologist in Bakersfield, California. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Vasculitis. His top areas of expertise are Angina, Degos Disease, Unstable Angina, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Singh is currently accepting new patients.

Supratim Banerjee
Advanced in Vasculitis
Dr. Supratim Banerjee
Cardiology
Advanced in Vasculitis
Dr. Supratim Banerjee
Cardiology

Comprehensive Cardiovascular Medical Group, Inc.

5945 Truxtun Ave, 
Bakersfield, CA 
 (2.4 miles away)
661-631-5544
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Banerjee received his medical degree from R.G. Kar Medical College, Calcutta, India. He joined the Cardiology Program at the University of Louisville, Kentucky where he had the opportunity to work with nationally known cardiogists in the field of Cardiovascular Diagnosis and Research. Devoting time to teaching resident doctors and medical students in the Bakersfield area, Dr. Banerjee loves his chosen field of medicine. He spends time with patients and their families to establish a strong physician/patient relationship.At Comprehensive Cardiovascular Medical Group, we believe we must be there for our patients, their families, our employees, our physicians, and our community. We remember that each patient is an individual, a member of a family and a member of a large community. Each patient requires a varied amount of physical, emotional, educational support from our team! It is our belief that every patient has the right to know the truth about his/her condition and that it is our duty to prepare patients for these truths and for their participation in decisions regarding their care. Dr. Banerjee is rated as a Distinguished provider by MediFind in the treatment of Vasculitis. His top areas of expertise are Glucocorticoid-Remediable Aldosteronism, Hypertension, Cardiomyopathy, and Atherosclerosis.

Brijesh K. Bhambi
Advanced in Vasculitis
Dr. Brijesh K. Bhambi
Cardiology | Interventional Cardiology
Advanced in Vasculitis
Dr. Brijesh K. Bhambi
Cardiology | Interventional Cardiology

Centric Health

2901 Sillect Ave, Ste 100, 
Bakersfield, CA 
 (0.1 miles away)
661-323-8384
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Our doctors are dedicated to treating you as an individual and advancing the research needed to provide a better way of life for you and your loved ones. Dr. Bhambi is rated as a Distinguished provider by MediFind in the treatment of Vasculitis. His top areas of expertise are Coronary Heart Disease, Angina, Atherosclerosis, Peripheral Artery Disease, and Heart Bypass Surgery.

VIEW MORE VASCULITIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sharma's expertise for a condition
ConditionClose
    • Distinguished
    • Angina
      Dr. Sharma is
      Distinguished
      . Learn about Angina.
      See more Angina experts
    • Atherosclerosis
      Dr. Sharma is
      Distinguished
      . Learn about Atherosclerosis.
      See more Atherosclerosis experts
    • Coronary Heart Disease
      Dr. Sharma is
      Distinguished
      . Learn about Coronary Heart Disease.
      See more Coronary Heart Disease experts
    • Advanced
    • Adenosine Deaminase 2 Deficiency
      Dr. Sharma is
      Advanced
      . Learn about Adenosine Deaminase 2 Deficiency.
      See more Adenosine Deaminase 2 Deficiency experts
    • Apoplexy
      Dr. Sharma is
      Advanced
      . Learn about Apoplexy.
      See more Apoplexy experts
    • Arterial Embolism
      Dr. Sharma is
      Advanced
      . Learn about Arterial Embolism.
      See more Arterial Embolism experts
    • Arterial Insufficiency
      Dr. Sharma is
      Advanced
      . Learn about Arterial Insufficiency.
      See more Arterial Insufficiency experts
    • Atrial Tachycardia
      Dr. Sharma is
      Advanced
      . Learn about Atrial Tachycardia.
      See more Atrial Tachycardia experts
    • Atrioventricular Nodal Reentrant Tachycardia (AVNRT)
      Dr. Sharma is
      Advanced
      . Learn about Atrioventricular Nodal Reentrant Tachycardia (AVNRT).
      See more Atrioventricular Nodal Reentrant Tachycardia (AVNRT) experts
    View All 21 Advanced Conditions
    • Experienced
    • Abdominal Aortic Aneurysm (AAA)
      Dr. Sharma is
      Experienced
      . Learn about Abdominal Aortic Aneurysm (AAA).
      See more Abdominal Aortic Aneurysm (AAA) experts
    • Abdominal Obesity Metabolic Syndrome
      Dr. Sharma is
      Experienced
      . Learn about Abdominal Obesity Metabolic Syndrome.
      See more Abdominal Obesity Metabolic Syndrome experts
    • Acute Coronary Syndrome
      Dr. Sharma is
      Experienced
      . Learn about Acute Coronary Syndrome.
      See more Acute Coronary Syndrome experts
    • Angioplasty
      Dr. Sharma is
      Experienced
      . Learn about Angioplasty.
      See more Angioplasty experts
    • Aortic Regurgitation
      Dr. Sharma is
      Experienced
      . Learn about Aortic Regurgitation.
      See more Aortic Regurgitation experts
    • Aortic Valve Stenosis
      Dr. Sharma is
      Experienced
      . Learn about Aortic Valve Stenosis.
      See more Aortic Valve Stenosis experts
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.